Enovis (NYSE:ENOV) Hits New 12-Month Low – Time to Sell?

Enovis Corporation (NYSE:ENOV) shares hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $17.30 and last traded at $17.9220, with a volume of 2658431 shares changing hands. The stock had previously closed at $18.22.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ENOV shares. Evercore set a $32.00 price objective on Enovis in a research report on Monday, July 6th. Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Citizens Jmp reduced their target price on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a research note on Wednesday, September 2nd. UBS Group reiterated a “buy” rating and set a $51.00 price target (up from $50.00) on shares of Enovis in a research report on Tuesday, July 28th. Finally, Citigroup restated a “market outperform” rating on shares of Enovis in a report on Wednesday, September 2nd. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $40.38.

Enovis Stock Down 4.4%

The business has a fifty day moving average of $24.70 and a 200 day moving average of $23.94. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84. The firm has a market cap of $1.03 billion, a P/E ratio of -0.93 and a beta of 1.31.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. The firm had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts predict that Enovis Corporation will post 3.15 EPS for the current year.

Insider Buying and Selling

In other news, insider Oliver Engert acquired 5,140 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The stock was purchased at an average price of $19.46 per share, for a total transaction of $100,024.40. Following the completion of the acquisition, the insider owned 61,238 shares in the company, valued at $1,191,691.48. This trade represents a 9.16% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Damien Mcdonald bought 13,035 shares of the stock in a transaction on Friday, September 4th. The stock was purchased at an average cost of $19.15 per share, with a total value of $249,620.25. Following the purchase, the chief executive officer directly owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. This represents a 5.57% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have purchased 23,293 shares of company stock valued at $449,599. Corporate insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

A number of large investors have recently made changes to their positions in the company. IFP Advisors Inc grew its position in shares of Enovis by 5,590.5% in the 2nd quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after purchasing an additional 1,174 shares during the period. Allworth Financial LP bought a new stake in Enovis during the 2nd quarter worth approximately $36,000. Integrated Wealth Concepts LLC acquired a new stake in Enovis during the 2nd quarter worth approximately $39,000. Public Employees Retirement System of Ohio acquired a new stake in Enovis during the 2nd quarter worth approximately $48,000. Finally, Annis Gardner Whiting Capital Advisors LLC lifted its stake in Enovis by 468,400.0% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 4,685 shares of the company’s stock valued at $107,000 after buying an additional 4,684 shares in the last quarter. Institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient mobility, support recovery and restore physical function. Its offerings serve orthopedic, sports medicine, rehabilitation and pain-management markets, with products used by healthcare professionals, athletes and patients.

The company’s product portfolio includes orthopedic braces and supports, surgical solutions, cold and compression therapy systems, rehabilitation equipment, physical therapy devices and recovery technologies.